End-of-life decisions as bedside rationing. An ethical analysis of life support restrictions in an Indian neonatal unit

INTRODUCTION

Hundreds of thousands of premature neonates born in low-income countries are implicitly denied treatment each year. Studies from India show that treatment is rationed even for neonates born at 32 gestational age weeks (GAW), and multiple external factors influence treatment decisions. Is withholding of life-saving treatment for children born between 28 and 32 GAW acceptable from an ethical perspective?

METHOD

A seven-step impartial ethical analysis, including outcome analysis of four accepted priority criteria: severity of disease, treatment effect, cost effectiveness and evidence for neonates born at 28 and 32 GAW.

RESULTS

The ethical analysis sketches out two possibilities: (a) It is not ethically permissible to limit treatment to neonates below 32 GAW when assigning high weight to health maximisation and overall health equality. Neonates below 32 GAW score high on severity of disease and efficiency and cost-effectiveness of treatment if one gives full weight to early years of a newborn life. It is in the child's best interest to be treated. (b) It can be considered ethically permissible if high weight is assigned to reducing inequality of welfare and maximising overall welfare and/or not granting full weight to early years of newborns is considered acceptable. From an equity-motivated health and welfare perspective, we would not accept (b), as it relies on accepting the lack of proper welfare policies for the poor and disabled in India.

CONCLUSION

Explicit priority processes in India for financing neonatal care are needed. If premature neonates are perceived as worth less than other patient groups, the reasons should be explored among a broad range of stakeholders.

National HIV treatment guidelines in Tanzania and Ethiopia: are they legitimate rationing tools?

OBJECTIVE

To provide an ethical analysis of whether the Ethiopian and Tanzanian national HIV/AIDS treatment guidelines can be considered legitimate and fair rationing tools.

METHOD

Qualitative study and ethical analysis involving guideline documents and interviews with nine key members involved in the development of the guidelines. The analysis followed an editing organising style. The theoretical framework was a guideline-specific framework based on theories of just resource allocation in healthcare and conditions that ensure fair processes in guideline development. According to this framework, legitimate rationing requires reasons for patient selection to be explicit, public and relevant, and decisions must be open to question and revision.

RESULTS

The only explicit rationing criteria that both guidelines recommended were clinical antiretroviral treatment indications. Explicit non-clinical rationing criteria were expressed in a separate Ethiopian implementation guideline. Neither of the guideline development processes fully satisfies minimal requirements of procedural fairness. There is a lack of transparency. The reasons for decisions are rarely given and are not publicly available. This reduces the opportunity for public questioning, debate and revisions. The guidelines were based on expert opinion and consensus. Recommendations from the WHO were copied without much discussion, disagreement or adjustment.

CONCLUSIONS

The two national HIV treatment guidelines discussed are de facto mechanisms for rationing but were developed using methods that do not fully satisfy the requirements of fair processes.

The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforts

In 1982, the European Organization for Research and Treatment of Cancer (EORTC) Radiotherapy Group established the Quality Assurance (QA) programme. During the past 20 years, QA procedures have become a major part of the activities of the group. The methodology and steps of the QA programme over the past 20 years are briefly described. Problems and conclusions arising from the results of the long-lasting QA programme in the EORTC radiotherapy group are discussed and emphasised. The EORTC radiotherapy group continues to lead QA in the European radiotherapy community. Future challenges and perspectives are proposed.

Development and diseases of the pancreas

The pancreas is a vital gland of exocrine and endocrine function. It is the target of two main affections: diabetes and pancreatic cancer. We describe the tissue interactions, signaling pathways and intracellular targets that are involved in the emergence of the pancreas primordium and its proliferation, morphogenesis and differentiation. It appears that several genes of developmental relevance have an adult function and are involved in pancreas affections. Embryological experimentation in animals contributed to provide candidate genes for human disease and holds promise for future treatments.

Normal tissue response to low doses of radiotherapy assessed by molecular markers--a study of skin in patients treated for prostate cancer

The aim of this study was to evaluate normal tissue response by molecular markers to multifraction low doses of ionizing radiation, with the focus on changes in repopulation, estimated using Ki-67 as the proliferation marker, and on expressions of the p53 and p21 proteins, identified as key proteins in the DNA damage checkpoint. Repeated skin biopsies were taken from patients treated for prostate cancer with radiotherapy. The expressions of Ki-67, p53 and p21 of the keratinocytes in the basal cell layer of the epidermis were quantified immunohistochemically. The dose to the basal layer was 1.1 Gy per fraction, given five times per week for seven weeks. The indices of the three markers were determined over the whole period. A significant suppression of the Ki-67 index was observed during the first weeks, followed by a significant gradual increase in the Ki-67 index over the last weeks. The p53 and p21 protein levels were almost zero in the unirradiated skin. Upon irradiation, both the p53 and p21 index increased in a pattern very congruent to the Ki-67 index. In conclusion, daily fractions of about 1 Gy to the skin resulted in, for the keratinocytes in the basal layer, a cell growth arrest for a couple of weeks and a subsequent acceleration in repopulation during the following weeks of irradiation. The present findings also provided novel insights into the role of the p53/p21 pathway in the response of a normal epithelium to ionizing radiation as it is applied in radiotherapy.

[Destiny-zapping--medical education, students' world view and the ethical challenge]

Three medical students describe their search for professional and personal identity midway through medical school. The article focuses on their concrete experience of human suffering and vulnerability, which is set against elements from the relational ethics of Danish philosopher KE Løgstrup. Løgstrup's ontology is based on a relational understanding of being human, and implicitly opposes the strongly objectivating and individualised view of human existence promoted through the experiences of everyday medical education.

Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer

The European Organization for Research and Treatment of Cancer (EORTC) Radiotherapy Group initiated its mailed thermoluminescence dosimetry (TLD) programme in 1986. The aim of the present study was to evaluate the clinical relevance of variations in beam output detected in the period 1993 to 1996. A total of 140 beam outputs were checked (26 for cobalt-60 units and 114 for linear accelerators) in 35 centres. Clinical dose-response data for tumour control and normal tissue morbidity were used to assess the variation in clinical outcome resulting from variability in beam output. For 75 checked beams with nominal accelerating potentials (n. a.p.) of 6 MV or less the mean ratio, +/- standard deviation (S.D.) of measured to stated output was 1.004+/-0.020. For 65 beams with n. a.p. of 8 MV or more, the ratio was 1.009+/-0.021. Even with this relatively high level of precision, broad distributions of estimated tumour control or normal tissue morbidity were found. In the 10% of the beams with the most pronounced underdosage, the loss in tumour control probability was estimated at 7-8 percentage points. Likewise, in the 10% of the beams with the most pronounced overdosage, the increase in mild/moderate morbidity was 19-22 percentage points. For severe morbidity the same beams raised the estimated incidence of severe complications from 5% to 9-10%. An estimation of the loss of uncomplicated cure probability was about 1% for both high and low energy beams. Sequential mailings considerably improved the uniformity of clinical outcome. We conclude that small deviations in beam output may lead to clinically important variations in outcome. Substantial reductions in the variation between measured and stated output can be achieved by sequential mailings. Mailed TLD checks should be an integral part of a continuously ongoing quality assurance activity in radiotherapy.

Soft tissue sarcoma after treatment for breast cancer--a Swedish population-based study

The aim was to quantify the risk of post-treatment sarcoma in breast cancer patients. All 122,991 women with a breast cancer from 1958 to 1992 in the Swedish Cancer Register were followed up for soft tissue sarcomas and 116 were found, giving a standardised incidence ratio of 1.9 (95% CI 1.5-2.2). The absolute risk was 1.3 per 10(4) person-years. The sarcomas were located in the breast region or on the ipsilateral arm in 63% (67/106). There were 40 angiosarcomas and 76 sarcomas of other types. In a case-control study, angiosarcoma correlated significantly with lymphoedema of the arm, odds ratio (OR) 9.5 (95% CI 3.2-28.0), but no correlation with radiotherapy was observed. For other types of sarcoma there was a correlation with the integral dose. The dose-response relationship indicated that the risk increased linearly with the integral dose to 150-200 J and stabilised at higher energies. The OR was 2.4 (95% CI 1.4-4.2) for an energy of 50 J, approximately corresponding to the radiation of the breast after breast-conserving surgery. Thus, only oedema of the arm correlated with angiosarcoma, but for other types of sarcoma the integral dose of radiotherapy was a predictor of the risk.

Absorbed dose determination at short distance from 60Co and 192Ir brachytherapy sources

This paper presents two methods for absorbed dose determination with ionization chambers at short distance from 60Co and 192Ir brachytherapy sources. The methods are modifications of the Bragg-Gray and large cavity principles given in the IAEA code of practice for high- and medium-energy photon beams. A non-uniformity correction factor to account for the non-uniform electron fluence in the air cavity is introduced into the methods. The absorbed dose rates were determined from ionization chamber measurements at distances between 1.5 and 5.0 cm from the brachytherapy sources. The agreement between the two methods is excellent in 60Co brachytherapy dosimetry. For 192Ir dosimetry, the difference is less than 2.5% at all distances. In absorbed dose rate calculations with the 60Co brachytherapy source, the ratios between calculated and experimentally determined absorbed dose rates are 0.987 and 0.994 depending on the method used for absorption and scatter correction. In 192Ir dosimetry, the large cavity principle gives almost identical values to those which can be obtained with the AAPM recommendations. Using the chambers according to the Bragg-Gray principle in 192Ir dosimetry, the agreement with AAPM calculated absorbed dose rates is within 2.5% at all distances. The uncertainty, expressed as one standard deviation, in the experimentally determined absorbed dose is estimated to be between 3 and 4%.

Correction factors for Farmer-type chambers for absorbed dose determination in 60Co and 192Ir brachytherapy dosimetry

This paper presents experimentally determined correction factors for Farmer-type chambers for absorbed dose determination in 60Co and 192Ir brachytherapy dosimetry. The correction factors were determined from measurements made in a PMMA phantom and calculation of ratios of measured charges. The ratios were corrected for the different volumes of the ionization chambers, determined in external high-energy electron beams. The correction factors for the central electrode effect and the wall material dependency in 60Co brachytherapy dosimetry agree with those used in external 60Co beam dosimetry. In 192Ir dosimetry, the central aluminium electrode increases the response of an NE2571 chamber compared with that of a chamber with a central graphite electrode. The increase is 1.1 and 2.1% at 1.5 and 5.0 g cm(-2) distance, respectively. Similar values are obtained with an NE2577 chamber. The wall correction factor in 192Ir dosimetry for a chamber with an A-150 wall has been determined to be 1.018, independent of the measurement distance. For a graphite walled chamber, the correction factor is 0.996 and 1.001 at 1.5 and 5.0 g cm(-2) distance, respectively. The values of the wall correction factors are evaluated by a theory presented. If the chamber is used according to the 'large cavity' principle, the correction factor to account for the replacement of the phantom material by the ionization chamber was determined to be 0.982 for an NE2571 chamber when used with a Delrin cap, and 0.978 for an NE2581 when used with a polystyrene cap. The correction factors for the 'large cavity' principle are valid at both 60Co and 192Ir qualities.

Calculation of absorbed dose distributions from dynamic wedges

In radiotherapy with photon beams, the use of dynamic wedges, which are obtained by the movement of one of the jaws, offers an increasing flexibility relative to the traditional use of metal wedges. But it is a disadvantage for the measurement of absorbed dose distributions, because the absorbed dose at each measurement point can only be obtained after a complete movement of the jaw. Consequently, for radiotherapy planning, an algorithm should be available that does not require measurements for any specific dynamically wedged beam, but is based on only a modest number of measurements. In this paper, an algorithm for the calculation of the dose distribution from dynamic wedges is described. This algorithm uses the convolution of pencil beam kernels with a non-uniform field function. These pencil beam kernels are derived from empirical data resulting from measurements of the open beam only.

Dose accuracy check of the 3D electron beam algorithm in a treatment planning system

The accuracy of the recently implemented three-dimensional electron beam dose calculating algorithm in CADPLAN version 2.62 manufactured by Varian Dosetek was investigated. The algorithm uses a generalized Gaussian pencil beam model and the dose distributions are calculated as the sum of three weighted Gaussians. To use the calculating program in an optimum way, one needs to know the dose calculation accuracy of the algorithm as well as its limitations. This investigation includes comparisons of measured relative dose distributions with calculated dose distributions and also comparisons of measured and calculated monitor units. The geometries tested were quadratic fields, irregularly shaped fields, oblique fields, irregularly shaped phantom surfaces and internal heterogeneities and were most often irradiated with 8 and 20 MeV electrons. The results indicate that the algorithm is well suited for clinical three-dimensional dose planning. Some deviations occurred but they were most often within the limits of international criteria of acceptability.

Practical implementation of enhanced dynamic wedge in the CadPlan treatment planning system

The Varian CadPlan algorithm for computation of relative dose distributions and monitor unit calculations for Enhanced Dynamic Wedge (EDW) fields is based on a combination of open field beam data and Segmented Treatment data Tables. Calculation of dose by the pencil beam convolution model uses scatter kernels and boundary kernels to create the distribution. The principles of the pencil beam convolution model is presented. Comparison of measured and calculated monitor units and relative dose distributions showed good agreement and the deviations are within international accepted tolerans. Test results indicate that the EDW model works satisfactorily for all energies and wedge angles.

Potential advantages of protons over conventional radiation beams for paraspinal tumours

BACKGROUND AND PURPOSE

Conformal treatment planning with megavoltage X-rays and protons was studied in an attempt to determine if there are advantage of boost therapy with protons instead of X-rays for a patient with a tumour growing around the cervical spinal cord.

MATERIALS AND METHODS

A patient with a Ewing sarcoma was selected for the model study. The proton boost plan was realised with a six beam patched technique. Several X-ray boost techniques were planned, some not yet practically realisable. The techniques giving the best dose distributions and the best tumour control probabilities in the absence of significant late toxicity were looked for. The boost techniques were added to two large lateral X-ray beams covering the planning target volume (PTV) and the main risk organ, the spinal cord. The evaluation was made with two biological models, i.e. the tumour control probability (TCP) model, proposed by Webb and Nahum (Webb, S. and Nahum, A.E. A model for calculating tumour control probability in radiotherapy including the effect of inhomogeneous distributions of dose and clonogenic cell density. Phys. Med. Biol. 38: 653-666, 1993), and the normal tissue complication probability (NTCP) model, first derived by Lyman (Lyman, J.T. Complication probability as assessed from dose-volume histograms. Radiat. Res. 104: s13-s19, 1985).

RESULTS

The comparison showed small but clear advantages of protons for the boost. At 1% NTCP in the spinal cord, the calculated TCP was on average 5% higher. However, depending on the values of the parameters chosen in the biological models, the gain for protons varied from 0-10%. The smallest gains were seen in radiosensitive tumours for which the TCP was close to 100% with any of the techniques and in radioresistant tumours for which neither technique resulted in any appreciable probability of local cure.

CONCLUSION

Protons appear to have therapeutic advantages over conventional radiotherapy in tumours with relatively high radiosensitivity situated close to the spinal cord.

Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland

PURPOSE

Localized prostate cancer was treated with combined external beam radiotherapy and high dose rate Ir-192 brachytherapy with the purpose of a high dose. The technical aspects of a modified treatment are described.

METHODS

The brachytherapy was given in two sessions preceded and succeeded by external beam radiation. The radioactive source was temporarily implanted by a remote afterloading device through six to 15 needles inserted transperineally guided by transrectal ultrasound. The entire prostate gland was included in the clinical target volume. The urethra and the tumour volume could be defined and irradiated to different dose levels in more than 90% of the patients.

RESULTS

Fifty-four patients were treated. The total dose to the prostate was approximately 70 Gy and to the tumour volume 80 Gy. By calculating the corresponding dose given by 2.0 Gy fractions, considering the radiobiology by using the LQ formula and assuming an alpha/beta value for prostate tissue of 10, the dose to the prostate was approximately 84 Gy and to the tumour volume 112 Gy. For the late effects to the urethra an alpha/beta value of 3 was used, which corresponds to 85 Gy. The brachytherapy could be given with accuracy except when the dorsal border of the prostate was concave. The dose distribution then tended to be less satisfactory. Post-treatment calculations showed that the maximum dose to the rectum was 67 Gy (radiobiologically corrected to 88 Gy), given in a small volume. The early side effects from the brachytherapy were minimal. The treatment could not be performed as intended in four patients; three patients had a narrow pelvis and in one patient the prostate was unusually resilient, preventing the needles from being positioned properly.

CONCLUSIONS

This modification of a previously reported brachytherapy technique for prostate carcinoma permits a high radiation dose to the tumour and to the prostate gland, which ultimately may improve local control.

Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma

PURPOSE

To evaluate the treatment outcome after radical radiotherapy of localized prostate cancer in 50 patients (38 patients with stage T1-2 and 12 patients with stage T3) after a median follow-up time of 45 months (range 18-92 months).

METHODS

The treatment was given by combination of external beam radiotherapy (50 Gy) and brachytherapy (2 x 10 Gy). The brachytherapy was given using TRUS-guided percutaneously inserted temporary needles with a high dose rate remote afterloading technique with Ir-192 as the radionuclide source. Three target definitions and dose levels inside the prostate gland were used. Local control was evaluated by digital rectal examination, TRUS-guided biopsies and serum PSA evaluations.

RESULTS

Clinical and biopsy verified local control was achieved in 48 of the 50 (96%) patients; for stage T1-2 in 37 of 38 (97%) patients and for stage T3 in 11 of 12 (92%) patients. A posttreatment serum PSA level < or =1.0 ng/ml was seen in 42 (84%) patients, values from >1.0 to < or =2.0 ng/ml were seen in four (8%) patients and values exceeding 2.0 were seen in four (8%) patients. The late toxicity was minimal.

CONCLUSION

The local control results and the minimal toxicity after the combined radiotherapy treatment are promising. However, long term results are necessary before general use.

Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy

OBJECTIVE

To describe local disease control after radical external beam radiotherapy of prostatic carcinoma, as judged by digital rectal examination (DRE), transrectal ultrasonography (TRUS)-guided biopsies and estimates of serum prostate-specific antigen (PSA).

PATIENTS AND METHODS

The study comprised 175 patients (mean age 67.5 years, range 49-82; > 90% aged > or = 60 years) with localized prostatic carcinoma (T1-T3C, N0, M0) who underwent external beam radiation therapy (70 Gy), and were then regularly followed with a DRE, measurements of serum PSA and TRUS-guided biopsies to determine the outcome.

RESULTS

The DRE revealed four patients with evidence of residual cancer in the prostate and biopsies showed no evidence of residual cancer in 131 (75%) of the patients. There was no correlation of residual cancer with tumour stage or grade but tumour size, as estimated by TRUS, correlated with the results of the biopsy. The nadir serum PSA level was < or = 1.0 ng/mL in 116 (66%) of the patients, of whom 76 (43%) had a nadir serum PSA level of < or = 0.5 ng/mL. The median time to the nadir level was 11 months. Serum PSA progression (> 4.0 ng/mL) at the latest PSA measurement after reaching the nadir occurred in 13% of the patients with a nadir PSA of < or = 0.5 ng/mL and in 25 of the 29 (86%) patients with a nadir serum PSA > 2.0 ng/mL. Cox regression analysis showed that tumour size and rectal irradiation dose were the most important factors for local control.

CONCLUSIONS

Radiotherapy is effective in achieving local control in small prostate cancer tumours but less effective in large tumours. Tumour size and dorsal extension of the irradiated target, the rectal dose, were the two important factors for local control. A serum PSA level of < or = 1.0 ng/mL was associated with a higher chance of prolonged disease control.

Fluence non-uniformity effects in air kerma determination around brachytherapy sources

In ionization chamber dosimetry close to brachytherapy sources, the non-uniform photon fluence in the vicinity of the air cavity of the ionization chamber must be corrected for. In this paper, experimentally determined relative non-uniformity correction factors are determined for a PTW23331 chamber and a number of Farmer-type chambers. It is concluded that the 'anisotropic' theory of Bielajew agrees better with the experimental results than the 'isotropic' theory of Kondo and Randolph. The experiments show that neither the material choice nor the radius of the central electrode have any significant effect on the non-uniformity correction factors. Experiments on the wall-material dependence in the non-uniformity correction factor, which is predicted by the anisotropic theory, were inconclusive. Parameters for the Farmer-type chambers for calculation of theoretical non-uniformity correction factors are given. Data to derive anisotropic fluence non-uniformity correction factors are given in tabular form. An error in the Kondo and Randolph equations is reported and the corrected equations presented.

Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer

PURPOSE

Since 1982, the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC) is carrying out a Quality Assurance program that includes the evaluation of the structure and human resources of 50 centers actively participating in protocols of clinical research in radiotherapy.

METHODS AND MATERIALS

One or two site visits were made by a team of radiation physicists and physicians. A detailed questionnaire was circulated to these radiotherapy centers to collect and update standardized figures on the status and activities of each center, to clarify some obscurities encountered during on-site visits, and to extend investigations to issues that were not addressed during local audits.

RESULTS

This article reports on departmental infrastructure, staff and equipment workload, and quality control procedures carried out by single institutions. Large variations in equipment and staff are observed among participating centers. Comparisons between data collected in the early 1980s and during a recent update show no difference in workload per megavoltage equipment and per simulator. The number of cancer patients treated per year per radiotherapist seems to slightly diminish, especially in centers that experienced a considerable staff shortage a few years ago. The most significant improvement is observed for the number of cases treated per year per member of the radiation physics team. The radiographer's workload shows an opposite trend.

CONCLUSIONS

Our database provides participating centers with strong comparative arguments to correct staff and equipment unbalances and to convince administrative authorities of priorities in decision making. The current analysis shows that the situation for equipment is unchanged in comparison with that observed 6 years ago. Efforts have to be put forth in some institutions to reduce the workload at simulators. A tentative profile and guidelines for minimum recommendations for European radiotherapy departments involved in clinical research are presented.

Soft tissue sarcoma after treatment for breast cancer

In a register study all women in the West of Sweden Health Care Region with a breast cancer diagnosed between 1960 and 1980 (n = 13,490) were followed up in the Swedish Cancer Register to the end of 1988 for later occurrence of a soft tissue sarcoma (STS). Nineteen sarcomas were reported, whereas 8.7 were expected and the relative risk (RR) was 2.2 (CI 95% 1.3-3.4). The absolute risk was 1.7/10(4) person years (PY) in comparison with 0.8 expected. To obtain a more detailed analysis of the associations between arm lymphoedema, radiotherapy and STS development, and to control the quality of the register data, a case control study was also performed. Clinical records from the different hospitals in the region were collected for all the 19 cases as well as for three selected controls per case. The histopathology of the cases were reviewed, and one of the cases was reclassified as a malignant melanoma and excluded from further analysis. Thirteen of the cases were clustered around the treated breast area. To quantify the exposure to radiotherapy, the integral dose was estimated. The presence of lymphedema was included as a binary variable in the analysis. The exact conditional randomisation test indicated a significant correlation between the integral dose and the development of an STS (p = 0.008) and this association was still significant after stratification for arm oedema. A conditional logistic regression analysis with STS as the dependent variable and the integral dose as the explanatory variable gave an odds ratio (OR) of 5.2/100 J (CI 95% 1.3-21.2), and if this regression was restricted only to the STS developing in the radiation fields the OR was 3.2/100 J (CI 95% 0.8-12.9). Thus, the excess of STS in this breast cancer cohort was very low (0.9/10(4) PY). However the integral dose correlates well to the development of STS and can be useful in quantifying even small risks of secondary malignancies in the breast cancer population.

EORTC guidelines for writing protocols for clinical trials of radiotherapy

The concept of a Master Protocol for phase III studies was raised at the Steering Committee of the EORTC Radiotherapy Group, in order to make the work of the study coordinators easier, when writing protocols and to give them more homogeneity. The Master Protocol defines and clarifies in a logical order the different steps which must be taken when designing a randomized trial--from the rationale to the references. It pays particular attention to eligibility criteria, volumes of interest defined in agreement with ICRU Report 50 (gross tumor volume, clinical target volume, planning target volume and organs at risk), simulation procedure, treatment technique, normal tissue sparing, dose computation, equipment, dose specification (also in agreement with ICRU Report 50). Last but not least, the different procedures of quality assurance for protocols and patients are also defined (site visits, dummy run procedure, in vivo dosimetry, individual case review) to allow working plans to be made in advance. We are aware that this work is not exhaustive, but hope that the contents will be of help to those who are writing a protocol.

The programme of quality assurance of the EORTC radiotherapy group. A historical overview

A quality assurance programme was activated in 1982 in the EORTC Cooperative Group of Radiotherapy. Definitions and contents of quality assurance and quality control, definitions of errors and deviations (systematic, occasional) are given. The methodology and steps of the quality assurance programme adopted over the past ten years are briefly described. The need for an interaction between national and international networks is emphasized. Consensus statements on quality assurance in radiotherapy provided during the January 1993 Geneva meeting conclude this introduction to the detailed reports on the quality assurance programme of the EORTC Cooperative Group of Radiotherapy.

Mailed TL dosimetry programme for machine output check and clinical application in the EORTC radiotherapy group

The Radiotherapy group of the European Organisation for Research and Treatment of Cancer (EORTC-RT) has been performing quality assurance with mailed TL dosimetry since 1986. The programme consists of therapy machine output checks, in vivo measurements, and dosimetry for brachytherapy. The therapy machine output checks have revealed a few large deviations (greater than 7%) between EORTC-measured and institute-stated dose, but also shown an improvement in the dosimetry of the participating institutes as a result of consecutive mailings. The use of in vivo dosimetry with mailed TLD has proven that it is feasible to detect deviations of +/- 5%. The results have shown deviations within +/- 5% for dosimeters located well within the radiation field for internal measurements in the pelvic region. Dosimetry of brachytherapy has been performed for low dose rate 192Ir sources. Differences of 14% can be seen between the participating centres.

EORTC radiotherapy group quality assurance: mechanical checks and beam alignments of megavoltage equipment

In 1987 mechanical checks of megavoltage units and simulators were included in the on-site physics program of the EORTC. The results reported were obtained in 16 different centres and concern 23 accelerators, 14 cobalt units and 14 simulators. In general, the deviations observed for accelerators and simulators are smaller than for cobalt units. A single score, based on the deviations observed for the mechanical checks, is attributed to each centre.

Quality assurance in brachytherapy: principles for ionization chamber measurement of absorbed dose close to brachytherapy sources

At present there exists no standardized procedure for absorbed dose determination with ionization chambers in the vicinity of brachytherapy sources. In this paper, a modification of the IAEA formalism for external photon beams is proposed in order to make it applicable at a reference point 20 mm from brachytherapy sources as well. A non-uniformity correction factor is introduced to correct for the effects of the steep absorbed dose gradient, and it is concluded that reasonable accuracy is possible when the Bragg-Gray principle is assumed to be valid.

Quality assurance in brachytherapy: the displacement effect in the vicinity of 60Co and 192Ir brachytherapy sources

Cylindrical ionization chambers with varying radii have been used to determine the displacement effect at distances between 10 mm and 40 mm from 60Co and 192Ir brachytherapy sources. Agreement with published values of the displacement factor for external 60Co beams is obtained. The shift between the centre of the ionization chamber and the effective point of measurement is found to be only a few per cent of the internal radius of the cylindrical ionization chamber. The shift is found to be dependent on the source to ionization chamber centre distance.

In vivo dosimetry with TLD in conservative treatment of breast cancer patients treated with the EORTC protocol 22881

Two anthropomorphic phantom breasts and six patients with breast carcinoma were irradiated according the prescriptions of the EORTC protocol 22881 on the conservative management of breast carcinoma by tumorectomy and radiotherapy. During the implantation procedure for an iridium-192 boost, three tubes were implanted, enabling the measurement with TLD rods of the dose within the breasts of the phantom and the patients during one fraction of the external x-ray therapy and during the interstitial therapy. Measured doses were compared with calculated values from a 2-D dose planning system. In general a fair agreement was found between the measured and calculated doses in points within the breast for the external beam therapy as well as for the interstitial treatment.

Entrance and exit TL-dosimetry in the conservative treatment of breast cancer: a pilot study for the EORTC-Radiotherapy Cooperative Group

Mailed dosimetry, using thermoluminescent dosimeters, can play an important role in quality assurance procedures in radiotherapy. In 1989, a pilot study was started with the main aim to show the feasibility of this method for the multicentre EORTC trial 22881 on the conservative management of breast carcinoma. Two anthropomorphic breast phantoms and six patients with breast carcinoma were irradiated according the prescriptions of the protocol. TLD measurements of the entrance and exit dose were performed in 6 MV tangential X-ray beams. It proved to be possible to correlate the dose measured in the entrance and exit points of the beams to the calculated dose closely under the surface. A thickness of at least 5 mm bolus material must be applied over the dosimeters and a distance of at least 3 cm from the lateral and medial field borders must be maintained in order to reach a clinically acceptable accuracy in the measurements.

Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC Radiotherapy and Breast Cancer Cooperative Groups and the EUSOMA (European Society of Mastology)

A consensus on a quality assurance programme of the treatment of early breast cancer was reached in a multidisciplinary meeting of surgeons, pathologists, radiotherapists, physicists and radiographers. Guidelines for treatment preparation and execution have been set up, including careful location and excision with marking of the primary tumour. The target volumes for irradiation of the whole breast and boost area have been defined. Radiation dose prescription rules, specification and checking procedures are given, together with measures to achieve a homogeneous dose within the target volume. The rules for a quality assurance programme in each clinic are designed for checking equipment and treatment method.

Quality audit of radiotherapy with EORTC mailed in water TL-dosimetry

A mailable TL-dosimetry (LiF) system has been designed and tested for the EORTC Radiotherapy Group for periodic monitoring of radiation therapy machines between and prior to on-site visits. Three TL-dosimeters were enclosed in a capsule which was placed in a holder and irradiated in photon beams in a water phantom. The institutes were instructed to irradiate the capsule to an absorbed dose of 2 Gy. After the irradiation, all capsules with dosimeter, the holder and completed data sheets were returned to Gothenburg for evaluation. The heating procedure used for reading the dosimeters was optimised regarding fading and reproducibility (less than 0.5%, 1. S.D.). The fading of the TL-signal was eliminated by adding an external annealing to the heating procedure. Both supralinearity and energy dependence were tested and routinely corrected for. The dosimeters were individually calibrated. During 1987, 1988 and the first part of 1989, dosimeters were mailed to 22 institutes, participating in clinical trials organised by the Radiotherapy Group. Of the 178 beams measured, 89% were within acceptable levels of variation for the absorbed dose states (less than or equal to 4%). The photon results gave a mean of 1.012 and a standard deviation of 0.025.

Primary radiotherapy for glottic laryngeal carcinoma stage I and II. A retrospective study with special regard to failure patterns

A retrospective study has been made of 302 patients with vocal cord carcinoma stage I and II treated between 1963 and 1983, emphasizing treatment failure patterns. The primary treatment modalities were radiotherapy for 266 patients and surgery for 36 patients. The minimum follow-up was 4 years. After primary radiotherapy there were 63 local recurrences and 7 neck lymph node recurrences, all appearing outside the target volume. The actuarial loco-regional recurrence-free rates at 5 years were 78% for T1, 76% for T2a (normal cord mobility) and 60% for T2b (impaired cord mobility) tumors. The actuarial regional lymph node recurrence-free rates at 5 years were 99, 100 and 93% for T1, T2a and T2b tumors respectively. The actuarial corrected survivals at 5 years were 95, 96 and 79% for T1, T2a and T2b tumors with primary radiotherapy and salvage surgery for recurrence. Salvage surgery was less successful in T2b compared to T1 and T2a tumors. In conclusion, after primary radiotherapy with salvage surgery the loco-regional control rate was high and very similar for glottic cancer T1 and T2a but less satisfactory for T2b tumors. Regional lymph node metastases were not a large problem in any of the subgroups. More effective radiotherapy with higher dose levels or an altered fractionation might increase the local control rate for T2 tumors with impaired cord mobility.

Quality assurance control in the EORTC cooperative group of radiotherapy. 3. Intercomparison in an anatomical phantom

Two papers concerning the quality control study organised by the EORTC (European Organisation for Research on Treatment of Cancer) Cooperative Group on Radiotherapy have been published. The medical profile (part 1) and the dosimetric intercomparison (part 2) of the participating institutions were presented. This part (paper 3) presents an integrated clinical and dosimetric investigation in an anatomical phantom. A tonsillar tumour and a homolateral subdigastric node were marked in an anatomical phantom. The institutions were asked to treat the phantom once like an ordinary patient. The phantom was loaded with dosimeters and irradiated. From the results obtained, it can be concluded that we did not find any major dosimetric problem related to absorbed dose calibration or calculation in the phantom. However, several major problems were related to non-optimal planning, treatment technique and dose distribution. The investigation shows the importance of a quality assurance programme for cooperative groups.

Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison

The European Organization for Research on Treatment of Cancer (EORTC) has performed site reviews at 17 institutions participating in clinical trials organized by the Cooperative Group of Radiotherapy. In this paper the dosimetric part of the quality assurance control programme is presented. In a previous paper (part 1) the medical profile of the participating centres was presented. In part 3 an integrated clinical and dosimetric investigation in an anatomical phantom will be presented. The deviations between the absorbed dose values, for specific points along the beam axis in a water phantom, determined by us and reported by the hospitals were within an acceptable level of variation (about +/- 3%) for 85, 70 and 71% of the 60Co gamma, X-ray and electron beams, respectively. In some scanning electron beams, too large deviations were found. The flatness and symmetry of the beams were measured. 73% of the X-ray and 60% of the electron beams were within the acceptable levels of variations. Dosimetric recommendations for institutions participating in EORTC clinical trials are presented.

Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer

A quality control study was carried out by the EORTC Cooperative Group of Radiotherapy. From January 1982 to December 1984, 17 institutions were visited by a group of "experts" in radiotherapy and radiation physics. The evaluation included three steps: a comparison of megavoltage units, technical and staff environment, and data present in clinical and radiotherapy charts for each center; radiation physics calibration of photon and electron beams; and radiation physics measurements on a stimulated clinical case using an Alderson Rando anatomical phantom. This paper presents the results of Part 1. The results of Parts 2 and 3 will be analyzed in separate papers. Large variations were observed in the number of patients treated per year, per radiotherapist, per radiation physicist and per technician. On average, 400 patients were treated per year per megavoltage unit, but 8/17 centers treated more than 500 patients per unit per year. The number of simulators was suboptimal in 12/17 centers. These observations were summarized by a workload and staff index, and this index shows that in 5/17 centers major problems are present which make it difficult to comply with all the requirements of EORTC protocols. The quality of work-up regarding tumor extension was considered to be satisfactory in all centers. Dental care in patients irradiated to the head and neck was not well organized in 5/17 centers. Interaction between CT scan and dosimetry treatment planning could be improved in most centers and this should be one of the primary objectives of future quality control.

The influence of irradiation time per treatment session on acute and late skin reactions: a study on human skin

A comparison of the radiation effect of altering the treatment time per session in fractionated radiotherapy was performed on human skin with 12 MeV electrons. Four fractions of 7.2 Gy were given within 22 days, once a week. The dose per fraction was administered in 4 min and 32 min, respectively. The dose rate was about 2 Gy/min and the prolonged treatment time was achieved by dividing each dose fraction into three equal subfractions with intervals of 14-15 min. Prolongation of the treatment time resulted in a significant reduction of the skin erythema (p less than 0.001), pigmentation (p less than 0.05) and the degree of telangiectasia at 5 years (p less than 0.001). The relative biological effectiveness (RBE) for the prolonged (32 min), in relation to that of the short (4 min) treatment time, RBE4 min/32 min, was 1.09-1.10 for erythema and 1.07-1.12 for telangiectasia. These findings indicate that prolongation of the treatment time per session has to be adjusted for in clinical radiation oncology.

Dosimetric intercomparison at the Scandinavian radiation therapy centres. I. Absorbed dose intercomparison

A dosimetric intercomparison was carried out at all the centres in Denmark, Norway and Sweden. All the beam qualities (except conventional roentgen rays) used in radiation therapy were investigated. The ratio of the absorbed dose measured by us to that stated by the centre was determined. The mean ratio and standard deviation with the reference field-size were for 60Co gamma beams 1.001 +/- 0.014, for roentgen ray beams (4-45 MV) 1.017 +/- 0.023, electron beams with energy E0 less than 10 MeV 0.989 +/- 0.027, and electron beams with energy E0 greater than or equal to 10 MeV 0.996 +/- 0.034. The difference between the highest and lowest ratios was 17.8 per cent. A systematic difference due to the application of different protocols (NACP 1972 and 1980) was found.

Ferrous sulphate dosimeter for control of ionization chamber dosimetry of electron and 60Co gamma beams

A check of the dosimetry using ionization chambers and applying the procedures described in the Nordic dosimetry protocols (NACP 1980, 1981) was carried out using the ferrous sulphate dosimeter as reference. Measurements have been carried out in electron beams in the energy range 2.8 to 27.5 MeV and in 60Co gamma beams. Consistent results were obtained with the two systems within about one per cent. Larger differences were only observed in electron beams containing a large proportion of scattered low energy electrons and contaminating roentgen rays which were not corrected for in the ionization chamber method.

Liquid ionization chamber for absorbed dose determinations in photon and electron beams

The use of a liquid ionization chamber for measurements in electron and photon beams with energies above 1 MeV has been investigated. The liquid in the chamber is 2,2,4-trimethylpentane. Fundamental properties such as the reproducibility of the measured charge per absorbed dose, the temperature dependence, and the angular dependence have been experimentally analysed. The general recombination losses in pulsed beams are shown to be dependent on the transport time of the ions in the liquid. For a longer transport time than the time between two consecutive pulses the losses depend on the mean dose rate and for a shorter transport time the losses depend on the absorbed dose per pulse. The Jaffe method is used for determination of the initial recombination losses, and compared with results from other authors. The chamber is particularly useful for absorbed dose determination in electron beams since the relation between measured charge and absorbed dose to water is almost energy independent. In photon beams the relation is somewhat quality dependent particularly at qualities below 10 MV. The change of the free ion yield caused by the small change of mean LET with the quality of the photon beam is probably the reason. Procedures for the calibration of the liquid chamber and the absorbed dose determination in electron and photon beams are described.

Calibration and use of plane-parallel ionization chambers for the determination of absorbed dose in electron beams

The dosimetry procedures to be used at electron energies, E0, below 15 MeV in order to determine absorbed dose to water with an ionization chamber have been investigated. The performance of different types of plane parallel ionization chambers was tested. A chamber suitable for use in accordance with the Nordic dosimetry recommendations was designed. Correction factors to be applied in order to use solid phantom materials instead of water were determined.

Postal intercomparison of absorbed dose for high energy x rays with thermoluminescence dosimeters

This study concerns the accuracy and precision of the IAEA/WHO LiF TLD system used in intercomparison by mail of absorbed doses from 60Co gamma-radiation and 4-25 MV x rays. The system employs 160 mg LiF powder in polystyrene capsules, which are placed at 5 or 7 cm depth in water and irradiated to doses close to 200 rad (2.00 Gy). The dosimeters are mailed to the IAEA Dosimetry Laboratory and read out under conditions to minimize variatons in instrument sensitivity. The precision of the readout technique, using 3 capsules per irradiation and the readout of 5 aliquots per capsule, is characterized by 0.2% standard deviation of the resulting mean. Since random errors during the irradiation are added, the detectable systematic descrepancy in dose delivery, at the 95% confidence level, is +/- 2% for 60Co gamma and +/- 3% for high-energy x rays.